Indo Us Biotech Limited (INDOUS) — Board Meeting | 12 August 2026
The board approved unaudited Q1 FY26 results showing revenue of ₹3,311.05 crores, up from ₹2,604.62 crores in Q1 FY25, with net profit of ₹303.74 crores versus ₹187.11 crores previously. EPS rose to ₹1.51 basic and ₹6.54 diluted. The meeting concluded in 40 minutes after reviewing financials and auditor reports.
About Indo Us Biotech Limited (INDOUS)
Fast Moving Consumer Goods · FMCG · Listed on NSE
📡 Get AI alerts when INDOUS files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track INDOUS — Free💡 Ask AI about this filing
📊 More INDOUS filings
- Announcement — 28 September 2026Indo US Bio-Tech Ltd announced that its insider trading compliance window will close on October 1, 2...
- 🔴 Annual Report — 5 September 2026Indo US Bio-Tech Limited reported a 15% revenue increase to **[amount context mismatch] crores** for...
- 🟡 Board Meeting — 5 September 2026Indo US Bio-Tech held its 22nd AGM on September 30, 2026 via video conferencing, adopting the 2025-2...
- 🟡 Board Meeting — 5 September 2026Indo US Bio-Tech held its 22nd AGM on September 30, 2026 via video conferencing, adopting the 2025-2...
- 🟡 Board Meeting — 5 September 2026Indo US Bio-Tech announced its 22nd Annual General Meeting will be held on 30 September 2026 via vid...
🔥 Also filed on 12 August 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when INDOUS files new disclosures
Track INDOUS filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track INDOUS — FreeFree account · 2 AI queries/day